Related Experiment Video
Updated: Jul 12, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
PSMA Radioligand Therapy in Prostate Cancer: Where Are We and Where Are We Heading?
Ludmila Santiago Almeida, Elba Cristina Sá de Camargo Etchebehere, Irene García Megías1
1Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, La Rioja, Spain.
Abstract:
Diagnosis and treatment of prostate cancer are complex and very challenging, being a major health care burden. The efficacy of radioligand therapy with prostate-specific membrane antigen agents has been proven beneficial in certain clinical indications. In this review, we describe management of prostate cancer patients according to current guidelines, especially focusing on the available clinical evidence for prostate-specific membrane antigen radioligand therapy.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET

